A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.

Professor Adrian Crellin, 70, noticed blood in his urine and promptly sought medical attention from his GP, leading to a ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men With Biochemically Recurrent Prostate Cancer Aug. 22, 2024 — The anti-cancer drug olaparib may be effective in ...

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), London, found that the drug NXP800, currently in trials for ovarian and ...